Journal of Pregnancy and Neonatal Medicine

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +441518081136

Perspective - Journal of Pregnancy and Neonatal Medicine (2023) Volume 7, Issue 3

Maternal-foetal medicine: Breakthroughs in high-risk pregnancy management.

Kirstin Webster*

Department of Anesthesiology and Perioperative Medicine, Columbia University, Netherlands

*Corresponding Author:
Kirstin Webster
Department of Anesthesiology and Perioperative Medicine
Columbia University, Netherlands
E-mail: kirstin56@cun.edu.com

Received: 27-May-2023, Manuscript No. AAPNM-23-102888; Editor assigned: 31-May-2023, PreQC No. AAPNM-23-102888 (PQ); Reviewed: 13-Jun-2023, QC No. AAPNM-23-102888; Revised: 20-Jun-2023, Manuscript No. AAPNM-23-102888 (R); Published: 24-Jun-2023, DOI: 10.35841/aapnm-7.3.147

Citation: Kirstin W. Maternal-foetal medicine: Breakthroughs in high-risk pregnancy management. J Preg Neonatal Med. 2023;7(3):147

Visit for more related articles at Journal of Pregnancy and Neonatal Medicine

Introduction

Maternal-Foetal Medicine (MFM) has experienced remarkable breakthroughs in the management of high-risk pregnancies, significantly improving outcomes for both mothers and foetuses. High-risk pregnancies present unique challenges due to factors such as pre-existing medical conditions, genetic abnormalities, and complications that may arise during pregnancy. In recent years, several advancements in MFM have revolutionized the management of these complex pregnancies, offering new avenues for diagnosis, intervention, and improved maternal and foetal care [1].

One significant breakthrough in MFM is the development and refinement of advanced prenatal screening and diagnostic techniques. Non-invasive prenatal testing (NIPT) has emerged as a game-changer in early detection of chromosomal abnormalities. By analyzing cell-free foetal DNA present in maternal blood, NIPT provides highly accurate results for conditions such as Down syndrome. This breakthrough has not only improved the accuracy of prenatal diagnosis but has also reduced the need for invasive procedures, such as amniocentesis or chorionic villus sampling, which carry a small risk of miscarriage. By providing early and reliable information about the foetus's health, NIPT enables informed decision-making, allowing parents to prepare and plan for the unique needs of their child [2].

In addition to prenatal screening, advancements in foetal therapy have transformed the management of high-risk pregnancies. Foetal therapy refers to interventions performed on the foetus while still in the womb, aiming to address specific conditions or complications. One breakthrough in this field is the development of minimally invasive procedures, such as foetal surgery or interventions performed using ultrasound guidance. These procedures allow for targeted treatment while minimizing risks to both the mother and the foetus. For example, in cases of twin-to-twin transfusion syndrome (TTTS), where blood flow between twins is imbalanced, laser ablation can be used to seal off abnormal blood vessels, improving the chances of survival and reducing complications. Similarly, interventions such as shunting can be performed to manage conditions like hydrocephalus, helping to prevent brain damage and other associated complications [3].

The advancements in MFM have also led to improvements in maternal care during high-risk pregnancies. High-risk pregnancies often require close monitoring and specialized care to address maternal health concerns and optimize outcomes. Breakthroughs in this area include the development of specialized clinics and multidisciplinary teams that bring together experts from various fields, such as obstetrics, maternal-foetal medicine, neonatology, genetics, and other relevant specialties. These collaborative efforts ensure comprehensive care and management tailored to the unique needs of high-risk pregnancies, promoting the well-being of both the mother and the foetus [4].

Furthermore, breakthroughs in high-risk pregnancy management have contributed to advancements in perinatal care, enhancing neonatal outcomes. Close collaboration between MFM specialists and neonatologists allows for seamless transition and planning of care for new-borns with complex medical needs. This includes optimizing delivery timing and method to reduce complications and improve survival rates. Additionally, advancements in neonatal intensive care have improved the overall survival and quality of life for premature infants and those born with congenital conditions, ensuring comprehensive care from the moment of birth [5].

Conclusion

Maternal-Foetal Medicine has witnessed remarkable breakthroughs in the management of high-risk pregnancies, leading to improved outcomes for both mothers and foetuses. Advanced prenatal screening techniques, such as NIPT, offer accurate and early detection of chromosomal abnormalities, allowing for informed decision-making and appropriate planning. Comprehensive care models involving multidisciplinary teams have enhanced maternal and neonatal care, optimizing outcomes and promoting overall well-being. These breakthroughs represent significant progress in highrisk pregnancy management and provide hope for improved outcomes in the future.

References

  1. Lim G, Soens M, Wanaselja A, et al. A Systematic Scoping Review of Peridelivery Pain Management for Pregnant People With Opioid Use Disorder: From the Society for Obstetric Anesthesia and Perinatology and Society for Maternal Fetal Medicine. Anesth Analg. 2022;135(5):912-25.

    2. Indexed at, Google Scholar, Cross Ref

  2. Crider KS, Williams JL, Qi YP, et al. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Cochrane Database Syst Rev. 2022;2022(2).

    3. Indexed at, Google Scholar, Cross Ref

  3. Nowakowski E, Dayananda S, Morgan M, et al. Obstetric pain management for pregnant women with opioid use disorder: A qualitative and quantitative comparison of patient and provider perspectives (QUEST study). Addiction. 2023;118(6):1093-104.

    4. Indexed at, Google Scholar, Cross Ref

  4. Sufrin C, Kramer CT, Terplan M, et al. Availability of medications for the treatment of opioid use disorder among pregnant and postpartum individuals in US jails. JAMA Netw Open. 2022;5(1):2144369.

    5. Indexed at, Google Scholar, Cross Ref

  5. Grebille AG, Mitanchez D, Benachi A, et al. Pericardial teratoma complicated by hydrops: successful fetal therapy by thoracoamniotic shunting. Prenat Diagn. 2003;23(9):735-9.

    6. Indexed at, Google Scholar, Cross Ref

Get the App